ArticleBMC cancer2023

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).

Linde Kehmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.